Hydrocortisone vs Prednisone: Which Corticosteroid Is Right for Your Condition?

How Hydrocortisone and Prednisone Differ at the Molecular Level

Hydrocortisone is identical to endogenous cortisol. Prednisone is a synthetic prodrug that the liver converts to prednisolone before it binds glucocorticoid receptors. That conversion step takes 30-60 minutes, which matters clinically in patients with severe hepatic impairment, who should receive prednisolone directly rather than prednisone.

Receptor binding explains most of the practical differences between the two drugs. Hydrocortisone binds glucocorticoid receptors with moderate affinity and mineralocorticoid receptors with significant affinity, roughly 1/1000th the potency of aldosterone but still enough to cause sodium retention at replacement doses. Prednisone, after conversion to prednisolone, binds glucocorticoid receptors with about four times the affinity of hydrocortisone and has negligible mineralocorticoid activity. That separation of effects is why endocrinologists choose hydrocortisone for adrenal insufficiency (it replaces both glucocorticoid and partial mineralocorticoid function) while rheumatologists and pulmonologists reach for prednisone when they want anti-inflammatory potency without fluid retention.

A 2021 review published in the Journal of Clinical Endocrinology and Metabolism confirmed that mean cortisol production in healthy adults is 5.7-7.4 mg/m² per day, equating to roughly 15-25 mg hydrocortisone in a person of average body surface area. [1] Prednisone 5 mg/day covers glucocorticoid needs on paper, but its long biologic half-life of 18-36 hours blunts the overnight cortisol nadir that normal HPA axis physiology depends on, which raises concerns about suppression of any residual adrenal function and metabolic side effects including hyperglycemia and dyslipidemia.

Potency, Equivalence Tables, and What They Miss

The classic steroid equivalence table places 20 mg hydrocortisone equal to 5 mg prednisone equal to 4 mg methylprednisolone equal to 0.75 mg dexamethasone. [2] Those ratios are useful for dose conversions but they obscure pharmacokinetic differences that determine real-world outcomes.

Prednisone's long duration means a single morning dose suppresses the HPA axis for most of the day. Hydrocortisone's short duration, with a plasma half-life of approximately 1.5 hours, requires multiple daily doses but allows an overnight recovery window during which ACTH can rise slightly before the first morning dose. That recovery window is physiologically desirable in partial adrenal insufficiency and in patients where HPA axis recovery after steroid taper is a goal.

Short acting. Long acting. Neither term captures everything that matters. The Endocrine Society 2016 Clinical Practice Guideline on adrenal insufficiency states: "We suggest using hydrocortisone or cortisone acetate as the preferred glucocorticoid formulation for patients with primary adrenal insufficiency." [3] That recommendation earned a Grade 2, QOEE moderate rating, reflecting good-quality evidence rather than expert opinion alone.

Adrenal Insufficiency: Why Hydrocortisone Is the Standard of Care

Primary adrenal insufficiency (Addison's disease) requires replacing both cortisol and aldosterone. Secondary and tertiary adrenal insufficiency require cortisol replacement only, because the renin-angiotensin-aldosterone axis remains intact. In both cases, hydrocortisone is preferred over prednisone for the following reasons.

First, dose precision. Addison's disease requires 15-25 mg hydrocortisone per day. An equivalent prednisone dose would be roughly 3.75-6.25 mg, a range where small pill-splitting errors produce clinically significant over- or under-replacement. Hydrocortisone's wider dose range in milligrams makes titration safer.

Second, diurnal rhythm. Healthy adrenal glands secrete roughly 50-60% of daily cortisol in the two hours after waking. [4] Conventional hydrocortisone taken as a 10 mg morning dose plus 5 mg early afternoon dose approximates that pattern. Prednisone, taken once daily, delivers sustained glucocorticoid exposure through the night when cortisol should be near its nadir, a pattern associated with worse metabolic outcomes in a 2014 cohort of 1,245 patients with adrenal insufficiency published in the European Journal of Endocrinology. [5]

Third, mineralocorticoid overlap. In primary adrenal insufficiency, fludrocortisone 50-100 mcg/day is added for aldosterone replacement, but hydrocortisone's weak mineralocorticoid activity provides a small supplemental buffer. Prednisone's negligible mineralocorticoid effect removes that buffer, meaning fludrocortisone dose adjustments become more sensitive to errors.

Modified-Release Hydrocortisone: Does It Beat Conventional Dosing?

Modified-release (MR) hydrocortisone formulations were developed specifically to produce a more physiologic cortisol profile from a single morning dose. Two products have reached clinical use: Plenadren (dual-release, EMA-approved 2011, Shire) and Chronocort (delayed-release evening formulation, designed to mimic the pre-dawn cortisol surge, Diurnal Group). [6]

The DREAM trial, a randomized crossover study (N=64) comparing Plenadren to conventional hydrocortisone, found that Plenadren produced lower mean 24-hour cortisol exposure (AUC reduced by 16%), lower fasting glucose, and lower LDL cholesterol after 12 weeks, with no difference in adrenal crisis rates. [7] Patients on Plenadren also had lower blood pressure (mean systolic reduction 3.7 mmHg, P<0.01) and a trend toward lower BMI.

Chronocort data are more preliminary. A phase 3 crossover trial (N=65) published in 2017 in the Journal of Clinical Endocrinology and Metabolism showed that Chronocort taken at 10 pm and 6 am generated a serum cortisol profile closer to healthy subjects than conventional hydrocortisone, but the drug was not approved in the US or EU as a standalone product during the trial period. [8]

Prednisone has no equivalent MR formulation for adrenal replacement. Lodotra (delayed-release prednisone) exists for rheumatoid arthritis to target the pre-dawn cytokine surge, but it was not designed to mimic cortisol physiology and carries the same HPA suppression risks as conventional prednisone.

The choice between conventional and MR hydrocortisone often comes down to cost and formulary access. Plenadren carries a substantially higher acquisition cost than generic hydrocortisone tablets, and US insurance coverage remains inconsistent. For patients with suboptimal metabolic profiles on conventional hydrocortisone, fatigue despite apparently adequate dosing, or recurrent hypoglycemia in the early afternoon, MR hydrocortisone is a reasonable next step before switching to prednisone.

DHEA Replacement in Addison's Disease: Evidence and Current Guidance

The adrenal cortex secretes dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) in quantities that collapse by more than 90% when the gland is destroyed in Addison's disease. Standard replacement with hydrocortisone and fludrocortisone does not restore DHEA, because neither drug stimulates DHEA synthesis. The question of whether to add oral DHEA, typically 25-50 mg once daily in the morning, remains one of the more contested areas in adrenal replacement therapy.

The evidence base is modest but directionally consistent. A Cochrane systematic review (10 randomized controlled trials, N=967) published in 2015 found that DHEA replacement in women with adrenal insufficiency produced small but statistically significant improvements in health-related quality of life (standardized mean difference 0.25 to 95% CI 0.07-0.44) and sexual function, with no significant effect on bone density or mood at 12 months. [9] The authors noted that the overall quality of evidence was low to moderate, limiting confidence in the estimates.

The Endocrine Society 2016 guideline offers a nuanced position: "We suggest a trial of DHEA replacement in women with primary adrenal insufficiency and decreased libido, depressed mood, or reduced sense of wellbeing despite otherwise optimized glucocorticoid and mineralocorticoid replacement." [3] That language is deliberate. The recommendation targets women specifically because men convert DHEAS to testosterone peripherally and rarely show DHEA deficiency symptoms when their testicular testosterone production is intact.

Practical DHEA prescribing involves checking a fasting 8 am serum DHEAS at baseline, targeting a mid-normal female reference range (roughly 75-200 mcg/dL for premenopausal women, lower for postmenopausal), and reassessing after three months. Androgenic side effects, including acne and hirsutism, appear at doses above 50 mg/day and are more common in women over 50 with lower androgen baseline levels. DHEA does not appear to affect cortisol pharmacokinetics or require adjustment of hydrocortisone dose.

Versus no DHEA. In clinical practice, the decision tree looks like this: if a woman with Addison's disease on optimized hydrocortisone and fludrocortisone still reports persistent fatigue rated more than 4 out of 10, low libido, or flat mood after six months of stable replacement, checking DHEAS and trialing 25 mg/day DHEA for 90 days is a low-risk intervention with a plausible benefit. If DHEAS comes back normal (which is uncommon in true Addison's but possible in early or partial disease), DHEA supplementation is unlikely to help.

Men with Addison's generally do not benefit from DHEA add-on unless they also have hypogonadism confirmed by low serum testosterone. In those cases, testosterone replacement is the more direct intervention.

Anti-Inflammatory and Immunosuppressive Indications: When Prednisone Wins

Outside adrenal replacement, prednisone outperforms hydrocortisone on almost every practical metric for inflammatory disease. Its four-fold greater potency per milligram means smaller tablets. Its once-daily dosing in most indications improves adherence. Its negligible mineralocorticoid activity avoids the peripheral edema and hypertension that complicate hydrocortisone use at anti-inflammatory doses (which would require 80-100 mg/day or more of hydrocortisone to equal a typical 20-40 mg prednisone burst).

Asthma guidelines from the Global Initiative for Asthma (GINA 2024) recommend oral prednisone or prednisolone 40-50 mg/day for five days as first-line treatment for severe acute asthma exacerbations in adults. [10] Hydrocortisone intravenously (100 mg every 6-8 hours) is reserved for patients who cannot take oral medications. That distinction reflects route and setting, not a preference for hydrocortisone in the outpatient setting.

For rheumatoid arthritis, the ACR 2021 guideline recommends using the lowest effective dose of any glucocorticoid as a bridge while disease-modifying drugs take effect, with a target of less than 5 mg prednisone-equivalent per day as quickly as tolerated. [11] Using hydrocortisone for this indication would require 20 mg or more per day split across multiple doses, an awkward regimen that most patients would not maintain.

Inflammatory bowel disease presents a mixed picture. Oral prednisone 40-60 mg/day is standard for moderate-to-severe Crohn's disease flares, while rectal hydrocortisone foam or enemas (Cortifoam, Colocort) are preferred for distal ulcerative colitis specifically because of the targeted local delivery that minimizes systemic absorption. Those are fundamentally different products solving different clinical problems, but they illustrate that hydrocortisone is not obsolete outside the endocrine suite.

Side Effects: Comparing the Risk Profiles

Both drugs share the class-effect side effects of glucocorticoid excess: hyperglycemia, weight gain, osteoporosis, skin thinning, adrenal suppression with prolonged use, immune suppression, and neuropsychiatric effects including insomnia and mood instability. The differences are a matter of degree and duration.

Bone loss is the side effect most influenced by drug choice. A prospective cohort study in JAMA Internal Medicine (N=4,256) found that long-term use of prednisone-equivalent doses above 7.5 mg/day was associated with a 2.3-fold increased risk of vertebral fracture compared with non-users (hazard ratio 2.31 to 95% CI 1.67-3.20, P<0.001). [12] Hydrocortisone at replacement doses (15-25 mg/day) carries a much lower fracture risk because the dose in cortisol-equivalents is still within the physiologic range. Patients on prednisone for more than three months at doses above 5 mg/day should be assessed for baseline bone density and started on calcium, vitamin D, and bisphosphonate prophylaxis per American College of Rheumatology guidelines.

Hyperglycemia risk scales with potency and duration of action. Prednisone's longer biologic half-life means postprandial glucose elevations persist into the evening and overnight, which complicates diabetes management. Hydrocortisone's shorter action concentrates glucose excursions in the morning hours, which is more predictable and easier to manage with insulin timing adjustments.

Sleep disruption is a common complaint with both drugs. Hydrocortisone taken late in the afternoon (after 3-4 pm) can produce cortisol-driven wakefulness. Prednisone taken in the morning sometimes still causes insomnia due to its overnight biologic activity. Shifting hydrocortisone dosing to no later than mid-afternoon is the first-line fix for hydrocortisone-related insomnia; for prednisone, dose timing adjustment has limited benefit because of the drug's long duration.

Sick-Day Rules and Stress Dosing: A Critical Safety Difference

Patients on hydrocortisone for adrenal insufficiency must double or triple their daily dose during febrile illness, surgery, or significant physical stress. This principle, called "sick-day dosing," is life-saving. Without it, the physiologic cortisol surge that healthy adrenal glands produce during acute illness does not occur, and adrenal crisis, which carries a mortality of roughly 6% per crisis episode, can develop within hours. [13]

Patients on long-term prednisone for inflammatory disease face the opposite problem. Chronic prednisone suppresses the HPA axis, so their own adrenal glands may not respond to stress even if prednisone is continued or increased. The question of how much to increase prednisone during illness is less standardized than the hydrocortisone sick-day rule, and patients often receive inconsistent advice.

Any patient on prednisone above 5 mg/day for more than three weeks should be assessed for HPA axis suppression before discontinuation. A morning cortisol level below 3 mcg/dL after 24 hours off prednisone suggests meaningful suppression. A level above 18 mcg/dL suggests the axis has recovered. Values in between (3-18 mcg/dL) warrant a formal ACTH stimulation test using 250 mcg cosyntropin with cortisol measured at 0 and 30 minutes. A peak cortisol above 18 mcg/dL at 30 minutes is considered a normal response by most US endocrinology centers. [14]

Patients on hydrocortisone for adrenal insufficiency should carry a medical alert bracelet and a prefilled syringe of hydrocortisone 100 mg for intramuscular self-injection in emergencies. Patients on prednisone for inflammatory disease rarely carry emergency injection kits, which creates a gap in safety education when their adrenal axis is more suppressed than either they or their prescriber realizes.

Switching Between Hydrocortisone and Prednisone

Switching from hydrocortisone to prednisone for anti-inflammatory indications (for example, a patient with Addison's disease who develops rheumatoid arthritis) requires careful math and timeline planning. The conversion is 20 mg hydrocortisone = 5 mg prednisone on a glucocorticoid potency basis, but the switch does not cover mineralocorticoid needs. Fludrocortisone must be continued at the same dose or potentially increased because prednisone contributes no mineralocorticoid effect.

Switching in the opposite direction, from prednisone to hydrocortisone during a taper for HPA recovery, is more common. The approach is to convert the prednisone dose to a hydrocortisone equivalent, administer it in split doses, and then taper the hydrocortisone by 2.5-5 mg every 2-4 weeks while monitoring morning cortisol. This taper is slower than most clinicians expect. Full HPA axis recovery after a six-month course of prednisone 20 mg/day may take another six to twelve months after discontinuation. Rushing the taper is the most common cause of secondary adrenal insufficiency presenting in the outpatient setting.